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Abstract
Background: Among patients with cystic fibrosis (CF), females have worse pulmonary function and survival than
males, primarily due to chronic lung inflammation and infection with Pseudomonas aeruginosa (P. aeruginosa).
A role for gender hormones in the causation of the CF “gender gap” has been proposed. The female gender
hormone 17b-estradiol (E2) plays a complex immunomodulatory role in humans and in animal models of disease,
suppressing inflammation in some situations while enhancing it in others. Helper T-cells were long thought to
belong exclusively to either T helper type 1 (Th1) or type 2 (Th2) lineages. However, a distinct lineage named Th17
is now recognized that is induced by interleukin (IL)-23 to produce IL-17 and other pro-inflammatory Th17 effector
molecules. Recent evidence suggests a central role for the IL-23/IL-17 pathway in the pathogenesis of CF lung
inflammation. We used a mouse model to test the hypothesis that E2 aggravates the CF lung inflammation that
occurs in response to airway infection with P. aeruginosa by a Th17-mediated mechanism.
Results: Exogenous E2 caused adult male CF mice with pneumonia due to a mucoid CF clinical isolate, the
P. aeruginosa strain PA508 (PA508), to develop more severe manifestations of inflammation in both lung tissue and
in bronchial alveolar lavage (BAL) fluid, with increased total white blood cell counts and differential and absolute
cell counts of polymorphonuclear leukocytes (neutrophils). Inflammatory infiltrates and mucin production were
increased on histology. Increased lung tissue mRNA levels for IL-23 and IL-17 were accompanied by elevated
protein levels of Th17-associated pro-inflammatory mediators in BAL fluid. The burden of PA508 bacteria was
increased in lung tissue homogenate and in BAL fluid, and there was a virtual elimination in lung tissue of mRNA
for lactoferrin, an antimicrobial peptide active against P. aeruginosa in vitro.
Conclusions: Our data show that E2 increases the severity of PA508 pneumonia in adult CF male mice, and
suggest two potential mechanisms: enhancement of Th17-regulated inflammation and suppression of innate
antibacterial defences. Although this animal model does not recapitulate all aspects of human CF lung disease,
our present findings argue for further investigation of the effects of E2 on inflammation and infection with
P. aeruginosa in the CF lung.
Background
Central to the pathogenesis of cystic fibrosis (CF),
inflammation and infection (especially by Pseudomonas
aeruginosa (P. aeruginosa)) are mutually reinforcing and
eventually lead to respiratory failure, with cor pulmonale
as the major cause of death [1,2]. The inflammatory
response accounts for the majority of the morbidity and
mortality of the disease [3]. Chronic P. aeruginosa
within the CF airway is a negative determinant of prog-
nosis [4] and the onset of mucoid P. aeruginosa coloni-
zation is associated with subsequent lung function
decline [5,6]. The lungs of CF patients infected with
P. aeruginosa have increased levels of pro-inflammatory
cytokines [7,8] and neutrophils in bronchoalveolar
lavage (BAL) fluid [9-11]. Similar findings have been
reported in CF mouse models of lung infection with
P. aeruginosa [12,13].
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were long thought to belong exclusively to either T
helper type 1 (Th1) or type 2 (Th2) lineages. However, a
distinct lineage named Th17 is now recognized that is
induced by interleukin (IL)-23 to produce IL-17 and
other pro-inflammatory Th17 effector molecules. Recent
evidence suggests a central role for the IL-23/IL-17
pathway in the pathogenesis of CF lung inflammation.
Human CF patients with active lung infection with
P. aeruginosa have elevated sputum levels of IL-23 and
of IL-17 [14,15]. Recent studies of adult male mice sug-
gested a role for IL-23, and the Th17 products it
induces, in the pathogenesis of murine lung inflamma-
tion and neutrophil recruitment in response to airway
infection with P. aeruginosa [15,16].
Among patients with CF, females have worse survival
than males (the so-called “gender gap”) [17,18]. Female
gender is an important independent risk factor for early
detection of mucoid P. aeruginosa [19] and for rate of
decline in pulmonary function in certain age groups
[20]. Females with CF scored worse on a health-related
q u a l i t yo fl i f es t u d y[ 2 1 ] ,a n da r es i g n i f i c a n t l ym o r e
likely to have acute pulmonary exacerbations, than their
male counterparts [22]. Both wild-type mice and CF
transmembrane conductance regulator (CFTR) knockout
mice exhibit a female disadvantage in mortality from
pneumonia due to a mucoid CF clinical isolate, the
P. aeruginosa strain PA508 (PA508) [13], and female
wild-type mice mount a stronger inflammatory response
in their lungs [23].
Although the cause of the CF gender gap has not yet
been identified, sex hormones can affect the immune
response [24,25]. The female sex hormone 17b-estradiol
(E2) has a complex immunomodulatory effect upon
inflammation. E2 suppresses acute lung inflammatory
responses of mice to lipopolysaccharide-induced injury
through an effect on vascular cell adhesion molecules
and proinflammatory mediators [26]. However, E2 can
also have a proinflammatory role depending on a variety
of criteria, as extensively reviewed by Straub [27].
Recent evidence indicates that E2 stimulates T-cell-
dependent immune responses [28].
E2 likely contributes to the pathogenesis of the CF
gender gap in ways other than direct effects on inflam-
matory mediators (reviewed by Zeitlin [29]). Coakley et
al [30] recently demonstrated that E2 reduces the
volume of the airway surface liquid of human CF airway
epithelial cells in vitro, to a degree that in vivo would be
expected to interfere with mucociliary clearance, a key
component of innate airway defence against infection
and inflammation. Chronic infection of CF airway by
P. aeruginosa is associated with the formation of bio-
films [31]. Since neutrophils enhance the formation of
P. aeruginosa biofilms [32], an activity of E2 to increase
neutrophil infiltrates in lung tissue and to increase neu-
trophils in the BAL fluids would be expected to have a
detrimental effect upon CF lungs. E2 may also modulate
the formation of P. aeruginosa biofilms through an
effect upon antimicrobial peptides such as lactoferrin
(LTF), a component of innate immunity that interferes
with bacterial biofilm development [33].
We tested the hypothesis that E2 aggravates the CF
lung inflammation that occurs in response to airway
infection with P. aeruginosa by a Th17-mediated
mechanism. We evaluated the effects of exogenous E2
upon lung infection with PA508 in adult male congenic
B6.129P2
Cftrtm1Unc homozygote mice. We assessed
inflammatory cell counts, differential cell counts and
bacterial burden in BAL fluid and in lung tissue. Lung
tissue inflammation was further assessed using hematox-
ylin and eosin stained sections and production of mucin
was assessed in airways and airway epithelial cells using
periodic acid Schiff - stained slides. We also measured
BAL fluid levels of inflammatory cytokines and the lung
tissue mRNA levels of IL-17A, IL-17F and IL-23, the
toll-like receptors 2 and 4 and the antimicrobial pep-
tides LTF (lung tissue) and prolactin-inducible peptide
(PIP) in trachea.
Materials and methods
Mice
Congenic B6.129P2
Cftrtm1Unc S489X (null) homozygote
male CF knock-out mice [34] were purchased from the
Case Western Reserve University’sA n i m a lC a r eF a c i l i t y ,
shipped in protective, filtered containers, transported in
climate-controlled trucks, and allowed to acclimatize for
at least 3 days in the vivarium prior to use. All proce-
dures were approved by the Animal Care Committee of
The Hospital for Sick Children, Toronto.
Injection of Hormone/Vehicle
Mice were injected intraperitoneally (i.p.) with 100 μLo f
Sesame seed oil (vehicle) with (treatment group) or
without (controls) 100 ng of E2 (Sigma, St. Louis, MO)
at 10:00 am for six consecutive days, and also at 22:00
pm in the first day.
PA508 Infection of Mice
O nt h ef i f t hd a yo fE 2t r e a t m e n t ,m i c ew e r ei n f e c t e d
with agar beads impregnated with 1 × 10
6 colony form-
ing units (CFUs) of P. aeruginosa strain PA 508 in
50 μL directly instilled into the distal trachea using the
method of Guilbault et al. [ 1 3 ] .B r i e f l y ,m i c ew e r e
anesthetized with ketamine and xylazine i.p., placed with
the mouth open in a position 30° from vertical on a cus-
tom-made restraining board and the tongue pulled
aside. The inoculum of infected agar beads was intro-
duced under direct vision into the trachea past the vocal
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Holliston, MA).
PA508, kindly provided by D. Radzioch (McGill Uni-
versity, Montreal, QC), was originally obtained from J
Lagacé (University of Montreal, Montreal, QC). This
strain has a mucoid appearance when grown on blood
agar and was originally isolated from the sputum of a CF
patient at Ste-Justine Hospital, Montreal, QC [13,35]. PA
508 was selected to take advantage of its mucoid pheno-
type and known pathogenicity in human cystic fibrosis
airways. Bacteria stocks were stored at -80°C until used.
Mouse weight
Mice were weighed immediately prior to PA508 infec-
tion and just before sacrifice.
Bronchoalveolar Lavage (BAL)
Immediately post-mortem, lungs were lavaged using
1.0 mL of ice cold 0.9% NaCl. Red blood cells were lysed
using ACK lysing buffer [36]. Cells were spun onto glass
slides and stained using the Diffquick method following
the manufacturer’s directions (Protocol® HEMA 3, Fisher
Scientific). Differential cell counts were obtained manu-
ally under light microscopy. 2-3× 100 cells were counted
per slide and means calculated. The supernatant was
kept at -80°C until assessed for cytokine content [36].
Lung Homogenates
Lungs from infected mice were harvested and homoge-
nized with Tenbroeck Tissue Grinders (Wheaton
Science Products, Millville, NJ) in 1 mL of sterile PBS
per 150 mg of tissue. Lung homogenate was centrifuged
at 500 g at 4°C for 10 min and then kept at -80°C until
assessed for cytokine content [36].
Inflammatory Cell counts and Differential Counts
Lungs were excised, minced, and digested for 50 min at
37°C with collagenase D and DNase I (each solution
1 mg/mL, Roche Applied Science). Erythrocytes were
lysed using ACK lysing buffer and then the remaining
cells were resuspended in staining buffer [37] containing
10% FBS for differential cell counts using flow cytome-
try. Cells were double stained with PE-anti-CD45 and
FITC-anti-Ly6G (Neutrophils), anti-F4/80 (macrophage)
(all from BD PharMingen) and fixed with 1.6% parafor-
maldehyde [37,38]. Labelled samples were analyzed on a
FACSCalibur (Becton Dickinso n ,S a nJ o s e ,C A ) .G a t i n g
of dead cells was performed using forward light scatter
and side light scatter. Analysis of data was performed
using FlowJo software (Tree Star, Inc.).
Lung Histopathology
Lungs were flushed with 0.9% NaCl, slowly inflated with
1 mL of formalin and then completely immersed in
formalin. Specimens were embedded in paraffin and
5 μm sections cut. Slides were stained for standard light
microscopy using hematoxylin and eosin, periodic acid
Schiff (Surgipath, Richmond, IL) and Masson’sT r i -
chrome (Sigma, St. Louis, MO) according to the manu-
facturers’ instructions.
Cytokine Measurements
Lung homogenates and BAL fluid were screened for
protein levels of 32 cytokines/chemokines/growth
factors (eotaxin, G-CSF, GM-CSF, IFNg,I L - 1 a,I L - 1 b,
IL-2, Il-3, IL-4, IL-5, IL-6,I L - 7 ,I L - 9 ,I L - 1 0 ,I L - 1 2
(p40), IL-12 (p70), IL-13, IL-15, IL-17A, IP-10, KC, LIF,
LIX, MCP-1, M-CSF, MIG, MIP-1a,M I P - 1 b,M I P - 2 ,
RANTES, TNFa, VEGF) with the Mouse Cytokine/
Chemokine Milliplex™Map kit (Millipore, Billerica, MA)
using Luminex™technology according to the manufac-
turer’s instructions, and assayed with the Luminex100-
IS™system by Linco Research, Inc. The cytokine
detection limit for this assay was 3.2 pg/mL.
Bacterial Burden
Serial dilutions of homogenate and BAL fluid were pla-
ted on Petri dishes containing tryptic soy agar. The
number of PA508 CFUs was counted after overnight
incubation at 37°C.
RNA Extraction and Real-time RT-PCR
We measured levels of mRNA encoding IL-17A, IL-17F
and IL-23, Toll-like Receptor 2 (TLR2), Toll-like Recep-
tor 4 (TLR4) and the antimicrobial peptides LTF in
whole lung tissue, and PIP in trachea. Total RNA was
extracted from lung or trachea using TRIZOL Reagent
(Invitrogen, Carlsbad CA) according to manufacturer’s
instructions, and reverse transcribed with SuperScript II
reverse transcriptase (Invitrogen, Carlsbad CA). Quanti-
tative real-time PCR was performed with the ABI
Prism™7900 (Applied Biosystems) using SYBR Green
(Eurogentec, San Diego, CA), normalizing all results to
the levels of GAPDH mRNA. The following primer
sequences were used:
IL-17A, sense 5’-TCCAGAAGGCCCTCAGACTA-3’,
anti-sense 5’-AGCATCTTCTCGACCCTGAA-3’.
IL-17F, sense 5’-GTGTTCCCAATGCCTCACTT-3’,
anti-sense 5’-GTGCTTCTTCCTTGCCAGTC-3’.
IL-23, sense 5’-GACTCAGCCAACTCCTCCAG-3’,
anti-sense 5’-GGCACTAAGGGCTCAGTCAG-3’,
LTF, sense 5’-GGAGCCTTGAGGTGTCTGAG-3’,
anti-sense 5’-CCAGGTGGCACTCCTTGTAT-3’.
TLR2, sense 5’-TGCTTTCCTGCTGGAGATTT-3’,
anti-sense 5’-TGTAACGCAACAGCTTCAGG-3’.
TLR4, sense 5’-GGCAGCAGGTGGAATTGTAT-3’,
anti-sense 5’-AGGCCCCAGAGTTTTGTTCT-3’.
PIP, sense 5’-TCCGAAAGCCACTTTTGATT-3’
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GAPDH, sense 5’-GCCATGGACTGTGGTCATGA-3’,
anti-sense 5’-TTCACCACCATGGAGAAGGC-3’.
Statistical Analyses
Data are reported as the mean ± standard error of the
mean unless stated otherwise. Using the statistical com-
ponent of the software package SigmaPlot V11.2 (Jandel
Scientific, SPSS Science, Chicago, IL) an unpaired t-test
was run to compare two different groups unless either
of the normality or equal variance tests failed, in which
case a Mann Whitney rank sum test was performed.
Ap a i r e dt-test was run to compare repeated measures
on a single group of individuals at two separate time
points. Differences were considered statistically signifi-
cant when p < 0.05.
Results
Mouse weight
Pre-infection weights were not statistically different
between control (21.55 ± 1.7 g, n = 6) and E2-treated
(23.8 ± 0.9 g, n = 8) mice, p ns. Weights decreased sig-
nificantly from pre-infection to sacrifice at two days
post-infection for both E2-treated (20.96 ± 1.0 g, n = 8,
p < 0.05) and control (20.47 ± 1.7 g, n = 6, p = 0.01,
paired t-test) mice. Weight loss expressed as a percent
of pre-infection body weight was significantly greater in
E2-treated (11.9 ± 2.2) than in control (5.1 ± 1.3) mice
(p < 0.05). None of the infected mice died prior to
sacrifice.
Inflammation
Compared to controls, E2-treated mice had significantly
higher counts of total white blood cells (WBCs) and of
polymorphonuclear cells (PMNs) in both whole lung
and BAL fluid (Figure 1). Hematoxylin and eosin (H&E)
stained sections of lung tissue revealed a marked inflam-
matory infiltrate in many areas of E2-treated mice but
little or no inflammatory infiltrate was noted in slides
from control mice (Figure 2A). Similarly, prominent
staining of mucin by Periodic Acid Schiff (PAS) was
widely distributed in multiple airway lining cells
throughout the large airways of E2-treated mice, stain-
ing that was virtually absent in control mice (Figure 2B).
However, no difference between groups in collagen
deposition was detected upon staining with Masson’s
Trichrome stain (data not shown).
The toll-like receptors (TLRs) 2 and 4 are important
components of the acute, innate inflammatory response
of normal and CF airway epithelial cells (reviewed in
[39]). In the E2-treated mice, lung tissue mRNA levels
for TLR2, but not TLR4, were increased significantly
(Figure 3). Levels of mRNA encoding IL-23 and IL-17A,
but not IL-17F, were increased (Figure 3).
IL-23 strongly induces the Th17 pro-inflammatory
phenotype in response to mucoid PA508 infection in
mice [15]. Therefore, we did a screening measurement
of protein levels in BAL fluid of a series of cytokines,
chemokines and growth factors, including known
Figure 1 Estrogen (E2) treatment is correlated with an increase
in inflammatory cells. In whole lung homogenate, (A) Total white
blood cells (WBCs), ** p <0.01 vs control, n = 5; and (B) neutrophils
(PMNs), * p < 0.05 vs control, n = 5. In bronchoalveolar lavage (BAL)
fluid, (C) Absolute cell counts of total WBCs, lymphocytes (lymph),
macrophages (M F) and PMNs, ** p < 0.0005, # p <0.005, vs
control, n = 5; and (D) PMN differential percentage, * p < 0.05 vs
control, n = 5.
Figure 2 E2 treatment is correlated with an increase in
inflammatory infiltrate and mucin in lung tissue sections.I n
lung tissue sections, E2 treated mice had (A) H&E stain:
inflammatory infiltrate (arrows) and (B) PAS stain: mucin producing
airway lining cells (Pink, arrows). Controls showed much less
inflammatory infiltrates or mucin producing cells. Light microscopy,
original magnification X 100, n = 4.
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Th17 downstream effector mediators. Although mea-
surement of the levels of IL-23 protein is technically
inconsistent, levels of IL-12(p40), one of two heteromers
making up the IL-23 protein, were increased by E2, as
were IL-6 and TNFa, also important early mediators
of acute lung inflammation that induce IL-17 (Figure
4). IL-17A itself, the prototype Th17 effector molecule,
and a series of downstream effectors that it modulates,
were also increased by E2, including G-CSF, MCP-1,
IL-1a,M I P - 1 a,L I F ,a n dM - C S F( F i g u r e5 ) .As e r i e so f
chemoattractant chemokines were increased by E2,
including MIP-2 (recruits neutrophils), eotaxin and
RANTES (eosinophils), MIP-1b (macrophages) and
IL-15 (mast cells) (Figure 6). CXCR3 chemokines that
regulate Th1 cell proliferation, IP-10 and MIG, and the
Th2 effector IL-5 were also increased by E2 (Figure 6).
Like MIP-2, KC and LIX are murine IL-8 homologs
that recruit neutrophils [40], but after E2 treatment
their protein levels did not change to a statistically sig-
nificant degree (Figure 7). Other protein levels that
were assessed but did not change significantly after E2
treatment included IFNg,I L - 1 b, IL-3, IL-4, IL-7, IL-9,
IL-10, IL-12(p70) (a component of IL-12 that, unlike
the p40 component, is not shared with IL-23), and
VEGF (data not shown).
Figure 3 E2 treatment is correlated with an increase in Toll
Like Receptor (TLR) 2 and IL-23/IL17A mRNA levels.E 2
increased (A) TLR2 (* p < 0.05), but not (B) TLR4 mRNA levels (p ns,
n = 5). E2 also increased (C) IL-23 and (D) IL-17A (p < 0.05), but not
(E) IL-17F (p > 0.05, n = 5).
Figure 4 E2 treatment is correlated with an increase in upstream regulators of Th17 Cells. E2 increased (A) IL-12(p40), one of two
heteromers making up the IL-23 protein, (B) IL-6, and (C) TNFa, important early mediators of acute lung inflammation that induce IL-17. * p <
0.05 vs control, n = 4.
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Page 5 of 13Figure 5 E2 treatment is correlated with an increase in downstream effectors of Th17 cells. E2 increased (A) IL-17A, the prototype pro-
inflammatory Th17 effector molecule, and a series of downstream effectors known to be modulated by IL-17A, including (B) G-CSF, (C) MCP-1,
(D) IL-1a, (E) MIP-1a, (F) LIF, and (G) M-CSF. * p < 0.05 vs control, n = 4.
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Page 6 of 13Figure 6 E2 treatment is correlated with an increase in chemoattractant chemokines. (A) MIP-2 (recruits neutrophils), (B) eotaxin and (C)
RANTES (eosinophils), (D) MIP-1b (macrophages) and (E) IL-15 (mast cells); in CXCR3 chemokines that regulate Th1 cell proliferation, (F) IP-10 and
(G) MIG, and the Th2 effector (H) IL-5. * p < 0.05 vs control, n = 4.
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E2-treated mice had more PA508 CFUs in whole lung
homogenate and in BAL fluid than controls (Figure 8).
Antimicrobial peptides
Levels of mRNA for the antimicrobial peptides LTF (in
lung tissue) and PIP (in trachea), part of the innate
immune system, were significantly reduced by E2 treat-
ment (Figure 8). The elimination of LTF mRNA levels
upon exposure to E2 was virtually complete, with an
average reduction of 200 - fold.
Discussion
Our present study demonstrates that exogenous E2
exerts a pro-inflammatory effect in a mouse model of CF
PA508 pneumonia. This is not surprising, given that both
wild-type mice and CFTR knockout mice exhibit a
marked female disadvantage in mortality from PA508
pneumonia [13] and female wild-type mice mount a
stronger inflammatory response in their lungs [23]. In
our adult male CF mice with PA508 pneumonia, E2
increased the numbers of inflammatory cells overall in
lung tissue and BAL fluid, with a selective increase in the
proportion and total number of neutrophils. Inflamma-
tory infiltrates and mucin production in lung tissue were
enhanced and the PA508 bacterial load in both lung tis-
sue and in BAL fluid was increased. These E2-induced
changes reproduce the phenotype reported in the female
mice in considerable detail, suggesting a central role for
E2 in causing the “gender gap” seen in this model.
Helper T-cells regulate inflammation. A lineage of
these cells named Th17, distinct from both Th1 and
Th2 lineages, is now recognized that is induced by inter-
leukin (IL)-23 to produce IL-17 and other pro-inflam-
matory Th17 effector molecules [41]. The development,
regulation and functional capacities of Th17 cells have
recently been reviewed [42]. Dubin and colleagues have
reported evidence for a central role of the IL-23/IL-17
pathway in the pathogenesis of human CF lung inflam-
mation [15]. They found elevated protein levels of
Figure 7 E2 treatment is correlated with an increase in a murine IL-8 homolog that recruits neutrophils, and in the growth factor G-
CSF that stimulates production of neutrophils. Protein levels of (A) MIP-2, but not (B) KC or (C) LIX, were increased, * p < 0.05, n = 4; (D) G-
CSF protein levels were increased, * p < 0.05, n = 4.
Wang et al. Respiratory Research 2010, 11:166
http://respiratory-research.com/content/11/1/166
Page 8 of 13IL-17A and IL-17F during an acute pulmonary exacer-
bation of chronic P. aeruginosa lung infection in the
sputum of adult CF patients, and in the BAL fluid of
pediatric CF patients unable to produce sputum, levels
that reduced dramatically following antibiotic treatment
[14,15]. They also found that neutrophil recruitment in
a murine model of P. aeruginosa lung infection is IL-23/
IL-17 dependent [16]. Thus recent lines of evidence
emphasize the correlation between levels of IL-23/IL-17
and the severity of lung inflammation in both CF mice
and in the human disease.
In our CF mice with PA508 pneumonia, E2 increased
protein levels in BAL fluid of TNFa and IL-6 (upstream
stimulators of IL-17 production) and also increased
mRNA levels in lung tissue of IL-23 and the isoforms
IL-17A and IL-17F. We then confirmed increased BAL
fluid protein content of IL-12(p40) (one of two hetero-
mers comprising the IL-23 molecule) [16], IL-17A and
downstream effector molecules: the pro-inflammatory
IL-1a,M I P - 1 a, IL-6 and the IL-6 family member
LIF, and chemoattractant chemokines that recruit macro-
phages (MCP-1), eosinophils (eotaxin and RANTES), and
monocytes (M-CSF). E2 also increased the chemoattrac-
tant chemokines, MIP-2 (recruits neutrophils), MIP-1b
(macrophages) and IL-15 (mast cells). There was no
increase in the products of Th1 or Th2 cells that suppress
the development of IL-17 producing T-cells, IFNg and
IL-4 respectively [41]. Together, these findings suggest
that the mechanism of the observed pro-inflammatory
effects of E2 in male CF mice involves stimulation of Th17
cells. Known or postulated intermediary interactions in
pro-inflammatory stimulation by E2 are shown in addi-
tional file 1.
It remains controversial whether, in human CF lung,
inflammation or infection precedes and initiates suscept-
ibility to the other [43], although there is increasing
recent evidence that the inflammatory response
accounts for the majority of the morbidity and mortality
of the human disease [3]. We contributed to a previous
review of lung inflammation as a therapeutic target in
CF [44]. Both inflammation and infection eventually
become chronic and severe in CF lungs [1], each aggra-
vating the severity of the other. A key feature of human
CF lung disease - that this [13] and similar [12] mouse
models of CF lung infection reproduce - is the marked
increase in BAL fluid of inflammatory cells, predomi-
nately of neutrophils, that is not successful in clearing
the P. aeruginosa infection [9-11]. Neutrophils particu-
larly enhance the formation of the very antibiotic-resis-
tant form of P. aeruginosa, biofilm [32]. IL-17 stimulates
t h ee x p r e s s i o no fI L - 8a n dG - C S Fi nh u m a na i r w a y
epithelial cells [45]. In our present study, E2 increased
both the proportion and absolute numbers of neutro-
phils in BAL fluid, consistent with the concept that E2
aggravates CF lung disease. Our data suggest the
mechanism may involve E2 enhancement of stimulation
of neutrophil production by the IL-17-responsive growth
factor G-CSF, as well as E2-induced IL-17 mediated
increases in levels of the chemoattractant murine IL-8
homolog (MIP-2) leading to increased recruitment of
neutrophils to the site of inflammation.
Antimicrobial peptides are important parts of the
innate immune system [46]. An exploratory study from
Baltimore reported a positive correlation between the
pulmonary function of CF patients as measured by the
FEV1 and levels in their BAL fluid of mRNA encoding
three specific antimicrobial peptides - LTF, PIP and
statherin [47]. Statherin is a potent human antimicrobial
peptide, but its mRNA was not detectable in mice.
Therefore, we focussed only on LTF and PIP. LTF is
active against P. aeruginosa [33]. It disrupts formation
of biofilm, the most pathogenic form of P. aeruginosa in
CF airways that is highly resistant to antibiotics. This is
done by chelating iron, in turn preventing P. aeruginosa
from accessing the iron it needs to make biofilm [33]. It
has been argued it is likely that during P. aeruginosa
-induced neutrophil necrosis, LTF (which is expressed
in human airways) is digested by proteases of neutrophil
and pseudomonal origin [32]. Thus, our finding of an
E2-induced increase in the number and proportion of
neutrophils in lung tissue and BAL fluid would be
expected to reduce LTF protein levels. Combined with
our demonstration of a greater than 99% reduction of
LTF mRNA in lung tissue, the overall direct and
Figure 8 E2 treatment is correlated with (A) an increase in
bacterial burden in whole lung and in BAL fluid, and with a
decrease in antimicrobial peptide mRNA levels for (B) LTF and
(C) PIP. * p < 0.05 vs control, n = 5.
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expected to substantially eliminate this component of
the innate immune defence against P. aeruginosa in the
airway. PIP is an antimicrobial peptide in the trachea,
the expression of which has been also shown to corre-
late positively with lung function in CF patients. It is
interesting to note that PIP mRNA levels in our CF
mice were reduced by E2, but it is not known to what
extent if any the relatively mild degree of reduction of
PIP mRNA levels in the lungs of our mice would have
any physiological effect on P. aeruginosa.
It is likely that E2 has more than one role in the
pathogenesis of the gender gap in human CF disease.
One possibility is that E2 further impairs the already
deficient ability of CF airway epithelial cells to activate
Cl
- secretion and thereby adequately hydrate the airway
surface liquid. A widely held hypothesis to explain the
predisposition of CF airways to chronic infection is that
reduced volume of isotonic periciliary airway surface
liquid impedes mucociliary clearance of pathogens and
hypoxic mucus [48]. We [49] and others [30] have
reported that normal menstrual changes in blood E2
levels are associated with changes in nasal potential dif-
ferences, in vivo measures of fluid and electrolyte trans-
port across the respiratory epithelium. Coakley and
colleagues found that the high blood E2 levels around
the time of ovulation are associated in vivo with an inhi-
bition of UTP-mediated Cl
- secretion in females with CF
[30]. Based upon studies of human bronchial epithelial
cell culture, they found that this inhibition is due to
changes in E2 concentration and not due to gender-
based differences in estrogen receptor levels.
The finding that E2 did not induce an increase in the
BAL fluid concentrations of some of the cytokines, che-
mokines and growth factors we assessed indicates that
the demonstrated range of increases in concentrations
of other inflammatory mediators is not simply an arte-
fact of a reduced airway surface liquid volume due to an
effect of E2 on transepithelial ion transport.
The association in E2-treated mice of increased signs
of inflammation with higher bacterial burden in both
the lung tissue and the BAL fluid illustrates the mutual
reinforcement of infection and inflammation in this
model. The anti-inflammatory IL-10, reported to be
r e d u c e di nP A 5 0 8i n f e c t i o ni nC F T Rk n o c k o u tm i c e
[13], was not altered in our present study. We speculate
that it might have been reduced had we examined mice
at a later and more florid stage in the pneumonia, but
this awaits further investigation.
Regulation of IL-17 has recently been proposed as an
attractive therapeutic approach for asthma [50], a com-
mon inflammatory respiratory condition involving eosi-
nophilic and neutrophilic infiltrates that often co-exists
in CF patients. A sex difference has long been
recognized in asthma, with females in the minority as
children but in the majority with more serious disease
as adults (reviewed in [51]). Indeed, it is attractive to
speculate that stimulation by E2 of Th17 pro-inflamma-
tory signaling in the lung may contribute to the sex dif-
ference in asthma as well as in CF.
Circulating levels of progesterone, as well as of E2, are
higher in sexually mature females than in males, with
cyclical menstrual changes in progesterone and E2
levels, and in the ratio of progesterone to E2. The activ-
ity of cytokine-secreting cells in vivo correlates with sex
hormone levels and fluctuates with menstruation [52].
Future study will be required to determine the effects of
progesterone and of menstrual fluctuations in the ratio
of circulating levels of progesterone to E2 on CF airway
inflammation and infection.
Recently, Chotirmall et al. reported that E2 inhibits
release by the human CF bronchial epithelial cell line
CFBE41o- of the pro-inflammatory IL-8 by up-regulat-
ing secretory leucoprotease inhibitor [53]. While
acknowledging that most published data in the field
have thus far emphasized the damaging effects over
time of uncontrolled chronic inflammation in CF lung,
the authors propose that acute surges of inflammation
may actually be protective in the context of an acute
exacerbation. If confirmed, this would imply that E2
inhibition of IL-8 during acute exacerbations would be
deleterious. This interesting suggestion remains to be
tested in an intact animal or human - considering the
possibility that effects of E2 upon a cell line in vitro,i n
the absence of cell-cell interactions, may not necessarily
correspond to the effects on the whole, intact animal or
human. Moreover, IL-8 is also produced by cell types
other than airway epithelial cells, including neutrophils,
of which there are large numbers in CF airway secre-
tions (reviewed in [54]). The effects of E2 upon neutro-
philic IL-8 production remain to be determined.
Although there is no exact murine homolog of IL-8,
three closely related functional homologs (MIP-2, KC
and LIX) have been identified in the mouse [40]. In our
present study, E2 increased BAL fluid levels of the pro-
inflammatory chemoattractant chemokine MIP-2, but
levels of KC and LIX failed to reach statistical signifi-
cance (p = 0.057). If, as our data suggest, increased
inflammation in CF is harmful even in acute exacerba-
tions, any anti-inflammatory activity of E2 would be
expected to be beneficial and thus would not contribute
to the pathogenesis of the observed CF gender gap.
Alternatively, deleterious increases in pro-inflammatory
mediators other than IL-8 and other effects of E2 (such
as inhibition of aspects of innate immunity or mucocili-
ary clearance) may more substantially aggravate CF lung
disease over time than any benefit from reduction
caused by E2 in IL-8 from airway epithelial cells during
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inflammatory contribution to the cause of the CF gen-
der gap. If E2 activity is harmful, E2 antagonists may
hold therapeutic potential for CF whether that harmful
activity is pro-inflammatory or anti-inflammatory. How-
ever, our present findings of increased inflammation in
response to E2 suggest anti-inflammatory approaches
may be beneficial.
We used the method of Guilbault et al. [13] to infect
the lungs of our mice. To avoid the confounding effects
of variability in circulating endogenous E2 levels asso-
ciated with the female estrus cycle, we studied only
adult male mice. Others using exactly the same strain of
CF mice have reported a higher female mortality in
response to acute exposure to intratracheal inoculation
with PA508, and therefore only used male mice in their
study [55]. Guilbault and colleagues have reported that
both wild type [23] and CF [13] mice demonstrate a
marked female disadvantage with respect to lung inflam-
mation and infection. Using the same model system,
instillation technique and PA508 clinical strain as in our
present work, they reported CF mice displayed a marked
female disadvantage in weight loss and mortality [13].
They too predominately used male mice in their studies
due to high mortality in the females. Furthermore, the
bacterial burden in lung tissue homogenates in females
was between 30- and 300-fold higher than with the
male mice. Yet, because of the high variability seen in
the females, they found no statistical significance could
be reached.
We examined our mice only two (rather than four)
days after intratracheal injection of the PA508-impreg-
nated agar beads in order to assess the degree of inflam-
mation at an earlier (and therefore presumably milder)
stage in the pathogenesis of the pneumonia, at a time
when we reasoned it might be easier to detect E2-caused
differences in inflammation. Our mice did not have any
fatalities, unlike the mice with P. aeruginosa pneumonia
described by the Montreal [23] or Cleveland [12] inves-
tigators, who were studied a later phase of the pneumo-
nia. Our control group, at this earlier stage, displayed
minimal evidence of lung tissue infiltration with inflam-
matory cells and negligible evidence of mucin, facilitat-
ing differentiation of the controls from the E2-treated
group which showed infiltrates and mucin production.
Conclusions
E2 treatment of adult male CF mice reproduced the
known features of the “gender gap” that are present in
an established model of CF PA508 lung infection. Pro-
inflammatory Th17 mediators (molecules of the IL-23/
IL-17 pathway) were increased and expression of antimi-
crobial peptides was inhibited, suggesting mechanisms
of E2 action. Transferring these results to the human
situation needs to be undertaken with caution, given the
differences between the anatomy and physiology of the
human and murine respiratory tracts and the differences
between the immune systems of the two species. More-
over, male mice injected with E2 alone are not the
equivalent of females. Nevertheless, the model repro-
duces important features of the human disease. Further
investigation of the mechanism(s) of E2 effects on
inflammation and infection with P. aeruginosa in the CF
lung is justified to assess the potential therapeutic
applicability in CF of the clinically available anti-estro-
gen compounds and of modulators of the Th17
pathway.
Additional material
Additional file 1: Conceptual network, showing known or
postulated intermediary interactions in pro-inflammatory
stimulation of CF mouse lung by E2. PMNs (neutrophils), MF
(macrophages), Eos (eosinophils).
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